HLF
Herbalife Ltd.
$13.88
-4.93% 2026-10-19
Consumer Defensive
HLFSPY
1W
+2.0%
1M
+16.7%
3M
+13.2%
6M
-18.3%
YTD
+7.7%
1Y
+58.3%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$1.4B
P/E (trailing)8.8
P/E (forward)4.5
52-week range7.56 – 20.40
Revenue growth (YoY, latest qtr)+5.4%
Dividend yield0.00%
Analyst consensusNone (3)
Mean price target$17.00 (+22%)
Valuation & fundamentals
Bottom line
Looks undervalued
Model read-out from the numbers below, not advice. Score +3 (DCF counts double).
▲DCF (base case)above the price by 181%
•Piotroski F-score5/9
•Altman Z2.5 (grey)
•Net debt / EBITDA2.7x
▲Analyst target+22% (3 analysts)
Discounted cash flow
Bear
$18
+28%
growth -3% · disc. 9.2% · term. 2.0%
Base
$39
+181%
growth 2% · disc. 8.2% · term. 2.5%
Bull
$71
+412%
growth 5% · disc. 7.2% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price implies shrinking cash flows: about -6% a year for 10 years.
Implied
-6%/yr
FCF, last 3 yrs
+9%/yr
FCF, last 5 yrs
-13%/yr
Revenue, last 3 yrs
-1%/yr
Revenue, last 5 yrs
-2%/yr
Same inputs as the DCF above: trailing free cash flow 0.3B, 8.2% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.79 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $3.08 vs trailing $1.57 (+96% expected growth). Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
77.7%
Operating margin
9.5%
FCF margin
6.2%
Net margin
3.2%
Return on equity
–
Return on invested capital
32.1%
Net debt / EBITDA
2.7×
Current ratio
1.2×
Interest cover
2.6×
Cash conversion (OCF/NI)
2.3×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved
Altman Z-score 2.5 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$17
+22%
Analysts
3
None
Range
$9–$25
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $5.0B | $228.3M | $252.9M |
| 2024 | $5.0B | $254.3M | $163.4M |
| 2023 | $5.1B | $142.2M | $222.5M |
| 2022 | $5.2B | $321.3M | $196.1M |
| 2021 | $5.8B | $447.2M | $308.9M |
| 2020 | $5.5B | $372.6M | $516.6M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -1.1%.
Earnings
Next report: 2026-11-02 · during market · EPS est 0.62
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | 0.54 | 0.51 | -4.9% |
| 2026-05-06 | 0.61 | 0.64 | +5.4% |
| 2026-02-18 | 0.48 | 0.45 | -5.6% |
| 2025-11-05 | 0.46 | 0.50 | +8.4% |
| 2025-08-06 | 0.50 | 0.59 | +18.6% |
| 2025-04-30 | 0.41 | 0.59 | +44.9% |
| 2025-02-19 | 0.22 | 0.36 | +64.0% |
| 2024-10-30 | 0.30 | 0.57 | +89.4% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $1.3B | +5.4% |
| 2026-03-31 | $1.3B | – |
| 2025-12-31 | $1.3B | – |
| 2025-09-30 | $1.3B | – |
| 2025-06-30 | $1.3B | – |
Analyst actions
Citigroup
PT $17
2026-08-07 · main
Buy → BuyPT $17
RBC Capital
PT $16
2026-04-28 · main
Sector Perform → Sector PerformPT $16
Mizuho
PT $15
2026-03-30 · main
Neutral → NeutralPT $15
Citigroup
PT $21
2026-02-19 · main
Buy → BuyPT $21
Mizuho
PT $13
2026-01-08 · main
Neutral → NeutralPT $13
Maxim Group
PT $20
2026-01-06 · init
→ BuyPT $20
Recent dividends
2014-02-28: $0.150 · 2013-11-07: $0.150 · 2013-08-09: $0.150 · 2013-05-10: $0.150 · 2013-03-01: $0.150 · 2012-11-09: $0.150 · 2012-08-10: $0.150 · 2012-05-11: $0.150
Insider trades
None
–
None · None
SELL–
News
1 Profitable Stock to Target This Week and 2 We Turn Down
StockStory · Oct 16
Herbalife (HLF) Is Up 12.2% After Announcing US$250 Million Buyback Program And Transformation Update – Has The Bull Case Changed?
Simply Wall St. · Oct 15
CPG Radar Launches AI-Powered Market Intelligence and Sales Platforms for Food, Beverage and Supplement Industries
PR Newswire · Oct 15
1 Surging Stock on Our Watchlist and 2 We Find Risky
StockStory · Oct 15
Herbalife India Launches Phyto Innovation Accelerator with IIT Madras to Advance India's Plant Biotechnology Ecosystem
PR Newswire · Oct 15
2 Cash-Producing Stocks to Own for Decades and 1 We Avoid
StockStory · Oct 13
3 Reasons to Avoid HLF and 1 Stock to Buy Instead
StockStory · Oct 08
Why Is Everyone Ignoring Celsius Stock's High Cash Yield?
Trefis · Oct 08
Stats refreshed 2026-10-19 17:46:51 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.